v3.26.3
License and Acquisition Agreements - Regeneron License Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
License and Acquisition Agreements            
Research and development   $ 32,786 $ 24,166 $ 101,160 $ 62,244  
Commercial product inventory   108,028   108,028   $ 54,895
Regulatory milestone            
License and Acquisition Agreements            
Intangible asset - Regulatory milestone   20,000   20,000   20,000
Regeneron | License agreement            
License and Acquisition Agreements            
Profit sharing recognized   105,821 63,282 269,447 159,446  
Regeneron | Clinical supply agreement            
License and Acquisition Agreements            
Research and development   0 $ 0 0 $ 0  
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured 90 days          
Notice period to terminate the agreement under payment-related breaches 30 days          
Consecutive suspension of activities period for termination of agreement 12 months          
Notice period to terminate the agreement 1 year          
Notice period to terminate the agreement if products are having safety concerns 3 months          
Commercial product inventory   $ 50,067   $ 50,067   $ 29,071